EEF2
Elongation factor 2
As of the edition of 20 October 2026, EEF2 (elongation factor 2, UniProt P13639) has 8 drugs tested at it and 12 companies on the list, 3 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P13639
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 29
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive; Nervous system; Hormones
- Registered trials of its drugs
- 106
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Stopped | 3 |
| Status not established | 2 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Denileukin diftitox | Marketed | Phase 4 | Ended 2011 |
| Tagraxofusp | Marketed | Phase 2 | Ends 2030 |
| Cintredekin besudotox | Stopped | Phase 3 | none listed |
| Moxetumomab pasudotox | Marketed | Phase 3 | Ends 2030 |
| LMB-100 | Stopped | Phase 2 | none listed |
| LMB-2 | Status not established | Phase 2 | none listed |
| Resimmune | Stopped | Phase 2 | none listed |
| Oportuzumab monatox | Status not established | Phase 3 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 3 |
| Undetermined | 6 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Virogen Biotechnology | Route A |
| Roche | Route A |
The other 9 companies at EEF2
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at EEF2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.